Kathleen,I've looked at medical news sites pretty frequently over the past few years, and I've noticed that generic producers are usually very quick to launch new products, sometimes shipping them on the day of FDA approval. I suppose since the profits are so huge and the timeframe is only six months, there is the incentive for the first generic drugmaker to be ready. I think that that most of the time the company that gets tentative approval first also gets final approval first, so in this case Par Pharma was probably expecting it. You may be right, though. But a few weeks might actually be a conservative estimate, surprisingly enough.Grant,I honestly have no idea how much the price will go down, so I won't even try to guess. Also, I could be mistaken but from following the news on this I think that Par Pharma only has exclusivity for the orally-disintegrating tablets, and that another company (which will probably be Dr. Reddy's) will get it for the regular Zofran tablets. So it's possible that competition between the two formulations will drive the price down some more but probably not enough to fit most people's definition of "cheap," at least not until the end of June when any producer can start making it. I think at least 25 companies have tentative approval for Zofran from the FDA, so the price competition will probably be pretty intense by summer.